Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

These cancer stem cells are resistant to chemotherapy and immunotherapy. A mutated RAS gene is found in some types of cancer including skin, pancreatic, lung and colorectal cancer. This mutation ...

Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company focused on developing novel therapies for cancer, has been making significant strides in its clinical pipeline, particularly in the ...

Professor Karen Gripp and his team from DuPont Hospital studied genetic mutations in H-ras gene which lead to Costello Syndrome, scientists found that the gene mutation occured in germline cells ...

Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 103,800 shares, a ...

The findings revealed that tumors with higher levels of RAS–RAF protein interaction were more likely to respond to KRASG12C inhibitors, a class of drugs designed to target the KRASG12C mutation.